235 related articles for article (PubMed ID: 29789417)
41. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.
Jäger E; Karbach J; Gnjatic S; Jäger D; Maeurer M; Atmaca A; Arand M; Skipper J; Stockert E; Chen YT; Old LJ; Knuth A
Cancer Immun; 2002 Sep; 2():12. PubMed ID: 12747757
[TBL] [Abstract][Full Text] [Related]
42. Identification of HLA ligands and T-cell epitopes for immunotherapy of lung cancer.
Neumann A; Hörzer H; Hillen N; Klingel K; Schmid-Horch B; Bühring HJ; Rammensee HG; Aebert H; Stevanović S
Cancer Immunol Immunother; 2013 Sep; 62(9):1485-97. PubMed ID: 23817722
[TBL] [Abstract][Full Text] [Related]
43. Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells.
Schwitalle Y; Linnebacher M; Ripberger E; Gebert J; von Knebel Doeberitz M
Cancer Immun; 2004 Nov; 4():14. PubMed ID: 15563124
[TBL] [Abstract][Full Text] [Related]
44. Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma.
Löffler MW; Mohr C; Bichmann L; Freudenmann LK; Walzer M; Schroeder CM; Trautwein N; Hilke FJ; Zinser RS; Mühlenbruch L; Kowalewski DJ; Schuster H; Sturm M; Matthes J; Riess O; Czemmel S; Nahnsen S; Königsrainer I; Thiel K; Nadalin S; Beckert S; Bösmüller H; Fend F; Velic A; Maček B; Haen SP; Buonaguro L; Kohlbacher O; Stevanović S; Königsrainer A; ; Rammensee HG
Genome Med; 2019 Apr; 11(1):28. PubMed ID: 31039795
[TBL] [Abstract][Full Text] [Related]
45. A combined approach of human leukocyte antigen ligandomics and immunogenicity analysis to improve peptide-based cancer immunotherapy.
Peper JK; Stevanović S
Cancer Immunol Immunother; 2015 Oct; 64(10):1295-303. PubMed ID: 25822767
[TBL] [Abstract][Full Text] [Related]
46. Population-level distribution and putative immunogenicity of cancer neoepitopes.
Wood MA; Paralkar M; Paralkar MP; Nguyen A; Struck AJ; Ellrott K; Margolin A; Nellore A; Thompson RF
BMC Cancer; 2018 Apr; 18(1):414. PubMed ID: 29653567
[TBL] [Abstract][Full Text] [Related]
47. HLA ligand profiles of primary renal cell carcinoma maintained in metastases.
Stickel JS; Weinzierl AO; Hillen N; Drews O; Schuler MM; Hennenlotter J; Wernet D; Müller CA; Stenzl A; Rammensee HG; Stevanović S
Cancer Immunol Immunother; 2009 Sep; 58(9):1407-17. PubMed ID: 19184600
[TBL] [Abstract][Full Text] [Related]
48. Induction of both CD8+ and CD4+ T-cell-mediated responses in colorectal cancer patients by colon antigen-1.
Maccalli C; Di Cristanziano V; Fodale V; Corsi D; D'Agostino G; Petrangeli V; Laurenti L; Guida S; Mazzocchi A; Arienti F; Perrone MP; Castelli C; Rivoltini L; Zagonel V; Tartaglia M; Parmiani G; Belardelli F
Clin Cancer Res; 2008 Nov; 14(22):7292-303. PubMed ID: 18974390
[TBL] [Abstract][Full Text] [Related]
49. Editing the immunopeptidome of melanoma cells using a potent inhibitor of endoplasmic reticulum aminopeptidase 1 (ERAP1).
Koumantou D; Barnea E; Martin-Esteban A; Maben Z; Papakyriakou A; Mpakali A; Kokkala P; Pratsinis H; Georgiadis D; Stern LJ; Admon A; Stratikos E
Cancer Immunol Immunother; 2019 Aug; 68(8):1245-1261. PubMed ID: 31222486
[TBL] [Abstract][Full Text] [Related]
50. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
[TBL] [Abstract][Full Text] [Related]
51. Dendritic cell-based immunotherapy for colon cancer using an HLA-A*0201-restricted cytotoxic T-lymphocyte epitope from tumor-associated antigen 90K.
Hee Lee J; Park MS; Hwang JE; Cho SH; Bae WK; Shim HJ; Kim DE; Chung IJ
Cell Mol Immunol; 2013 May; 10(3):275-82. PubMed ID: 23524651
[TBL] [Abstract][Full Text] [Related]
52. The HLA Ligandome Comprises a Limited Repertoire of O-GlcNAcylated Antigens Preferentially Associated With HLA-B*07:02.
Mukherjee S; Sanchez-Bernabeu A; Demmers LC; Wu W; Heck AJR
Front Immunol; 2021; 12():796584. PubMed ID: 34925382
[TBL] [Abstract][Full Text] [Related]
53. Validation of immunogenic PASD1 peptides against HLA-A*24:02 colorectal cancer.
Soh JE; Abu N; Sagap I; Mazlan L; Yahaya A; Mustangin M; Khoo TS; Saidin S; Ishak M; Ab Mutalib NS; Jamal R
Immunotherapy; 2019 Oct; 11(14):1205-1219. PubMed ID: 31478431
[TBL] [Abstract][Full Text] [Related]
54. Mechanisms of loss of HLA class I expression on colorectal tumor cells.
Browning M; Petronzelli F; Bicknell D; Krausa P; Rowan A; Tonks S; Murray N; Bodmer J; Bodmer W
Tissue Antigens; 1996 May; 47(5):364-71. PubMed ID: 8795136
[TBL] [Abstract][Full Text] [Related]
55. IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4(+) T cells.
Ohno Y; Kitamura H; Takahashi N; Ohtake J; Kaneumi S; Sumida K; Homma S; Kawamura H; Minagawa N; Shibasaki S; Taketomi A
Cancer Immunol Immunother; 2016 Feb; 65(2):193-204. PubMed ID: 26759006
[TBL] [Abstract][Full Text] [Related]
56. p21-ras-peptide-specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly-->Asp).
Fossum B; Gedde-Dahl T; Breivik J; Eriksen JA; Spurkland A; Thorsby E; Gaudernack G
Int J Cancer; 1994 Jan; 56(1):40-5. PubMed ID: 7903287
[TBL] [Abstract][Full Text] [Related]
57. Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction.
Abelin JG; Harjanto D; Malloy M; Suri P; Colson T; Goulding SP; Creech AL; Serrano LR; Nasir G; Nasrullah Y; McGann CD; Velez D; Ting YS; Poran A; Rothenberg DA; Chhangawala S; Rubinsteyn A; Hammerbacher J; Gaynor RB; Fritsch EF; Greshock J; Oslund RC; Barthelme D; Addona TA; Arieta CM; Rooney MS
Immunity; 2019 Oct; 51(4):766-779.e17. PubMed ID: 31495665
[TBL] [Abstract][Full Text] [Related]
58. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
[TBL] [Abstract][Full Text] [Related]
59. Immunodominance across HLA polymorphism: implications for cancer immunotherapy.
Kim CJ; Parkinson DR; Marincola F
J Immunother; 1998 Jan; 21(1):1-16. PubMed ID: 9456431
[TBL] [Abstract][Full Text] [Related]
60. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer.
Saeterdal I; Bjørheim J; Lislerud K; Gjertsen MK; Bukholm IK; Olsen OC; Nesland JM; Eriksen JA; Møller M; Lindblom A; Gaudernack G
Proc Natl Acad Sci U S A; 2001 Nov; 98(23):13255-60. PubMed ID: 11687624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
